A 14-gene molecular assay can help identify patients with lung cancer who could benefit from chemotherapy after surgery, according to results of a study presented at the 2025 American Society of ...

A single dose of the human papillomavirus vaccine confers protective immunity against infection on par with two doses, according to results from the NCI’s ESCUDDO trial, potentially making it easier ...

Drug companies are pouring billions of dollars into PD-1×VEGF bispecific antibodies, hoping these dual-action drugs can outperform existing immunotherapy and anti-angiogenic combinations in lung ...

Merck and Daiichi Sankyo pulled their accelerated approval application for patritumab deruxtecan (HER3-DXd), an antibody–drug conjugate (ADC) that targets HER3, under study against certain lung ...

1Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. 2Division of Hematology/Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon. ...

Major Finding: Iron activation within the lysosome triggers oxidative membrane lipid degradation and ferroptosis. Concept: Fentomycin-1 induces phospholipid oxidation and ferroptosis in cancer cells ...

Bristol Myers Squibb (Princeton, NJ), Princeton, NJ.

Inavolisib (Itovebi; Genentech) boosted survival in patients with HR-positive, HER2-negative advanced breast cancer and extended the time they could wait before starting chemotherapy. In the phase III ...

Findings from a multinational study suggest that adding an AI-integrated platform to training masterclasses for pathologists boosts their accuracy in classifying HER2-stained breast cancer samples, ...

Genentech will collaborate with Orionis Biosciences to discover and develop molecular glues for cancer, the companies announced today. Molecular glues are small molecules that bind to, and promote ...

Treatment with lurbinectedin (Zepzelca; Jazz Pharmaceuticals) and atezolizumab (Tecentriq; Genentech) improved overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC) ...

Major Finding: An inflammatory signature is a prognostic biomarker for CAR T-cell failure in non-Hodgkin lymphoma. Concept: InflaMix uses results from common blood tests to predict survival and ...